CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

简称 CRIT REV ONCOL HEMAT ·UNITED STATES ·出版周期 Monthly ·年均收录 252 篇

5.6

最新影响因子

2.40%

自引率

一般来源Elsevier官网：83%

投稿难度

偏慢,4-8周来源Elsevier官…

审稿周期

期刊简介

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY是一本专注于肿瘤学和血液学领域的国际学术期刊，ISSN号为1040-8428，由荷兰出版商ELSEVIER出版，出版地为阿姆斯特丹，出版周期为月刊。该期刊的影响因子较高，具体数值需参考最新JCR报告，属于SCI收录期刊，中科院分区通常位于医学大类的高分区（如1区或2区）。该期刊为非开放获取（非OA）期刊。其发文特点以高质量的综述文章为主，涵盖肿瘤学和血液学的基础研究、临床实践及转化医学等领域，尤其关注新兴治疗方法和前沿进展。杂志的质量较高，审稿严格，但作为综述类期刊，原创性研究较少，可能存在时效性相对滞后的问题，投稿时需注意其对综述深度和创新性的要求。

影响因子趋势

近期发表

Hippo-YAP1 dysregulation as a central driver of therapeutic resistance in cancer: Mechanisms and targeting therapeutic strategies 2026-08-22

CAR-T cell therapy-associated coagulopathy: From immunothrombotic storm mechanisms to precision management strategies 2026-08-21

From site-centered to patient-centered: Promises and challenges of decentralized clinical trials in oncology 2026-08-22

Novel clinical intervention pathway based on the pathogenesis mechanism of Enterotoxigenic Bacteroides fragilis 2026-08-25

PARP inhibitors and the tumor micro-environment: Bidirectional crosstalk, resistance mechanisms, and therapeutic opportunities 2026-08-26

Irradiation-based development of tumor vaccines: Mechanistic insights and translational exploration 2026-08-06

Bacillus Calmette-Guérin (BCG) with or without immune checkpoint blockade in BCG-naïve high-risk non-muscle-invasive bladder cancer: A systematic review and reconstructed individual patient data meta-analysis 2026-08-06

Immune checkpoint inhibitors in cancer patients with pre-existing autoimmune disease: Comparative safety and efficacy in a registered systematic review 2026-08-18

From granulomas to nanomotors: Active surveillance and microenvironment mapping in the post-tuberculosis Lung 2026-08-21

CAR-T Cell Therapy for Glioblastoma: Obstacles and Advances 2026-08-21